ADENOID CYSTIC CARCINOMA

This early-phase study tests a new drug called XMT-1660 in about 319 people with advanced solid tumors, including breast, ovarian, and endometrial cancers. The main goals are to find the safest dose and check for side effects. Researchers will also see if the drug shrinks tumors.…

This study tests two different oral drug combinations in people with a rare type of salivary gland cancer called adenoid cystic carcinoma (ACC) that has a specific genetic change (NOTCH mutation). The goal is to see if combining a NOTCH-blocking drug (CB-103) with either abemacic…

This trial investigates whether combining two drugs, camrelizumab and famitinib, can help people with rare head and neck cancers that have spread or cannot be removed by surgery. The study includes four types of these cancers and aims to see how safe and effective the treatment i…

This study tests a new drug called REM-422 in people with advanced adenoid cystic carcinoma (ACC), a rare cancer of the glands. The drug works by breaking down a specific genetic message (MYB mRNA) that helps the cancer grow. The trial will enroll 125 participants to see if the d…

This early-phase trial tests the safety of CRD3874-SI, a drug that activates the STING pathway to boost the immune system against cancer. About 81 adults with advanced solid tumors (sarcoma, Merkel cell carcinoma, and others) will receive weekly IV infusions at increasing doses. …

This early-phase trial tests AVA6000, a chemotherapy drug that is designed to activate only in tumors, potentially reducing side effects. About 158 adults with advanced solid tumors (like breast, ovarian, or salivary gland cancer) will receive the drug intravenously. The main goa…

This phase 2 trial tests a combination of two drugs—becotatug vedotin (a targeted antibody-drug conjugate) and epirubicin (a standard chemo)—in 40 people with EGFR-positive, recurrent sinonasal adenoid cystic carcinoma that cannot be surgically removed. The goal is to shrink the …

This study is for people with a rare sinus cancer called sinonasal adenoid cystic carcinoma. The treatment delivers high-dose chemotherapy directly to the tumor through a small tube in an artery, aiming to shrink it as much as possible. After three sessions, doctors check if the …

This phase II trial is testing a drug called puxitatug samrotecan (AZD8205) in 28 adults with an aggressive form of adenoid cystic carcinoma that has spread or come back. The study aims to see if the drug is safe and effective for this specific cancer subtype. Participants will r…

This study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control the tumors when other treatments have stopped working. Up to 28 adults will receive treatment for up to 12 months, an…

This study tests a new drug (MRG003) alone or with another drug (putrelimab) in people with salivary gland cancer that has come back or spread. The goal is to see if these treatments can shrink tumors or stop them from growing. About 90 adults will take part, and the study is not…

This phase 2 trial tests whether the drug sacituzumab govitecan can help control salivary gland cancer that has come back or spread to other parts of the body. About 30 adults whose cancer cannot be removed by surgery or cured with radiation will receive the drug through an IV. R…

This study tests a drug called enfortumab vedotin in people with adenoid cystic carcinoma (ACC), a rare cancer that has come back or spread. The goal is to see if the drug can shrink tumors or slow the disease. About 34 adults will take part, and researchers will monitor side eff…

This study tests an experimental drug called VMD-928, taken as a pill, either alone or with another cancer drug (pembrolizumab). It is for adults with advanced solid tumors or lymphoma that have not responded to or are no longer controlled by available treatments. The goal is to …

This early-stage trial is testing an experimental oral drug called RGT-61159 in about 105 people with two types of cancer that have come back or stopped responding to treatment: adenoid cystic carcinoma (a rare salivary gland cancer) and colorectal cancer. The main goals are to c…

This study tests whether giving focused radiation (SBRT) early to people with adenoid cystic carcinoma that has spread to a few spots can slow the cancer's growth. About 32 participants will either receive SBRT or standard care. Researchers will track how long the cancer stays un…

This early-stage trial tests a new drug called NN3201 in people with advanced cancers that have a specific marker called c-Kit. The drug is designed to deliver a chemotherapy agent directly to cancer cells, potentially killing them while sparing healthy tissue. The study will enr…

This study follows people with a rare and advanced cancer of the nasal cavity and sinuses called T4 sinonasal adenoid cystic carcinoma. All participants receive the standard treatment: surgery followed by radiation therapy. The goal is to measure how long people live without the …